Targeted Therapy Drugs for Waldenstrom Macroglobulinemia
Acalabrutinib (Calquence) is a Bruton tyrosine kinase inhibitor that is approved for treatment of Waldenstrom macroglobulinemia.
A clinical review of agents that target specific pathogenic proteins in Waldenstrom macroglobulinemia, summarizing mechanisms of action, approved indications, common adverse events, and levels of supporting evidence.
Waldenstrom macroglobulinemia is a rare lymphoplasmacytic lymphoma that causes IgM‑producing cells to accumulate. Targeted therapy with BTK inhibitors provides a disease‑specific, orally available option that can control disease activity while sparing many toxicities associated with conventional chemotherapy.
Evidence level: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Related signals
- Waldenström Macroglobulinemia Clinical Trials
- European Consortium for Waldenström's Macroglobulinemia
- Waldenström Macroglobulinemia - A State-of-the-Art Review: Part 2- Focus on Therapy
- The therapeutic perspective of relapsed/refractory Waldenström Macroglobulinemia: what comes next?
- Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia